ClinicalTrials.gg
TerminatedNCT06943937Updated Oct 14, 2026

A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

A Phase 1 interventional study of YTS109 cell injection in Lupus Nephritis (LN) and Immune Thrombocytopenia (ITP), sponsored by China Immunotech (Beijing) Biotechnology Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by China Immunotech (Beijing) Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The decision was not based on safety concerns. Enrolled participants will complete safety follow-up per protocol.
Updated Oct 14, 2026Now TerminatedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Enrollment
87th of 88
2 · median 51
Started
2025
with 18 others
Phase 1
15 of 96
11 open now
Registered
73rd of 96
by date
Lead sponsor
4 of 96
China Immunotech (Beijing) Biotechnology Co., Ltd.

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 87th largest by enrollment of the 88 interventional ones that give a count, is one of 19 that started in 2025, is one of 15 in phase 1, and was the 73rd registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

This study evaluates the safety and efficacy of YTS109 cells in adults with refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus-Immune Thrombocytopenia (SLE-ITP). Approximately 36 patients aged 18-65 will receive a single infusion of YTS109 cells (1×10⁶-2×10⁶ cells/kg). The primary endpoint is observations of types, severity, and frequency of dose-limiting toxicities (DLTs) and adverse events (AEs). Secondary endpoints include the complete renal response (CRR) rate at week 12 in LN, and proportion of subjects achieving complete response (CR) or partial response (PR) at week 12 post-treatment in SLE-ITP. This single-arm, open-label trial will enroll patients across Beijing GoBroad Hospital in China.

Read the detailed description

Background: Systemic lupus erythematosus (SLE) is characterized by multi-system and multi-organ involvement, recurrent flares and remissions, and the presence of numerous autoantibodies. LN and SLE-ITP are the most common and severe clinical manifestations of SLE. Recently, the therapeutic advancements have been made in the management of SLE. However, the patients with refractory SLE, particularly those complicated by LN and SLE-ITP, continue to face significant unmet clinical needs. CAR-T cell therapy has emerged as one of the innovative therapeutic modalities for autoimmune diseases, characterized by its controllable safety profile and durable therapeutic efficacy, warranting further clinical exploration and investigation in the future. YTS109 cell is a universal allogeneic STAR-T cell therapy targeting CD19, designed to efficiently eliminate B cells in patients with SLE and mitigate autoimmune responses. Design: This is a single-center, single-arm, prospective exploratory clinical trial designed to evaluate the safety profile, preliminary therapeutic efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of YTS109 cell therapy in patients with refractory SLE. Approximately 36 patients aged 18-65 will receive a single infusion of YTS109 cells (1×10⁶-2×10⁶ cells/kg). The primary endpoint is observations of types, severity, and frequency of dose-limiting toxicities (DLTs) and adverse events (AEs). This study was approved by the IRB of Beijing GoBroad Hospital (Approval Number: RP2025-013-002), All participants provided written informed consent.

03

Conditions studied

  • Lupus Nephritis (LN)
  • Immune Thrombocytopenia (ITP)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment in this study:

  1. Age ranges from 18 to 65 years old (including threshold), regardless of gender.
  2. Meet the EULAR/ACR 2019 SLE Classification Criteri:

Cohort 1: Lupus Nephritis: Defined as failure to achieve remission after treatment with and ≥2 (e.g., CTX, tacrolimus, MMF, cyclosporine) and/or biologics, with urine protein/creatinine ratio (UPCR ≥1.0 g/g) , and renal pathology requirement scriteria: ISN/RPS 2003 Class III/IV proliferative lupus nephritis (or combined with type V features) , with ≤50% glomerulosclerosis.

Cohort 2: Refractory Immune Thrombocytopenia: Requires treatment failure with: Failed treatment with at least 1 course of MP shock (1g for 3 days) or high- dose glucocorticosteroids (1mg/kg/d equivalent dose of glucocorticosteroids) in combination with 1 or more immunosuppressive agents. At least 2 consecutive routine blood tests for less than 50×10\^9/L and >30×10\^9/L were performed prior to enrolment. other non-SLE causes of thrombocytopenia, such as infections, myelosuppression and hypersplenism, were excluded.

3. Essential Organ Function Criteria:

  1. Bone marrow: Neutrophils ≥1×10\^9/L (within 2 weeks, excluding granulocyte colony-stimulating factor use).

    ≥60 g/L.

  2. Liver: /AST ≤3× (disease-related elevations permitted).

    ≤1.5×ULN (disease-related elevations permitted).

  3. Renal: ≥30mL/min (Cockcroft-Gault formula, excluding acute declines).
  4. Coagulation: /PT ≤1.5×ULN.
  5. Cardiovascular: Hemodynamic stability. 4. Fertile females or males with partners of childbearing age must use medically approved or abstain during and ≥12 months post- treatment. Negative serum HCG test (within 7 days pre-enrollment) for fertile females; non-lactating.

5. Voluntary participation with signed and compliance.

Exclusion criteria

Exclusions Criteria:

Subjects who meet any of the following exclusion criteria will not be admitted to the study:

  1. Severe drug allergies or .
  2. Uncontrolled/untreated infections (fungal, bacterial, viral, etc.).
  3. CNS disorders (exceptions: epilepsy, psychosis, organic brain syndrome, cerebrovascular accident, encephalitis, CNS vasculitis).
  4. Heart failure intolerance.
  5. Congenital immunoglobulin deficiency.
  6. within 5 years (exceptions: localized cancers with negligible risk).
  7. End-stage renal failure.
  8. Subjects positive for: / HBcAb with HBV DNA > detection limit; Ab + HCV RNA; Ab; Syphilis test.
  9. Deep vein thrombosis/pulmonary embolism within 6 months pre- screening.
  10. Severe mental illness/cognitive impairment.
  11. Participation in other clinical trials within 3 months pre-screening.
  12. Use of (within 5 half-lives) or biologics (within 4 weeks) pre-screening.
  13. Pregnancy/breastfeeding or planned conception.
  14. Other researcher-determined ineligibility.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    YTS109 cell

    Subjects will receive YTS109 cell (1E6 STAR+T cell/kg or 2E6 STAR+T cell/kg) once in this study.

    Drug: YTS109 cell injection

Interventions

  • Subjects will receive YTS109 Cell Injection(1E6 STAR+T cell/kg or 2E6 STAR+T cell/kg) once in this study.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    1. Dose-limiting toxicity (DLT); 2. Types, severity, and frequency of adverse events (AEs).

    Time frame: 28 days for DLT during the treatment assessment period, and observation AEs will be conducted up to 52 weeks post-treatment.

Secondary outcomes

  1. Efficacy Evaluation in LN

    The proportion of subjects who achieved complete renal response (CRR) at 12 weeks

    Time frame: The complete renal response (CRR) rate at week 12 in LN, and observation will be conducted up to 52 weeks post-treatment.

  2. Efficacy Evaluation in SLE-ITP

    The proportion of subjects achieving complete response (CR) or partial response (PR) at 12 weeks

    Time frame: The proportion of subjects achieving complete response (CR) or partial response (PR) at week 12 post-treatment in SLE-ITP, and observation will be conducted up to 52 weeks post-treatment.

  3. Peak Plasma Concentration (Cmax) of YTS109

    To evaluate the metabolic characteristics of YTS109

    Time frame: These detections will be conducted up to 52 weeks post-treatment.

  4. Time to Peak (Tmax) of YTS109

    To evaluate the metabolic characteristics of YTS109

    Time frame: These detections will be conducted up to 52 weeks post-treatment.

  5. Area under the plasma concentration versus time curve (AUC) of YTS109

    To evaluate the metabolic characteristics of YTS109

    Time frame: These detections will be conducted up to 52 weeks post-treatment.

  6. PD parameters

    Changes in B cells quantification and phenotypic in peripheral blood

    Time frame: These detections will be conducted up to 52 weeks post-treatment.

07

Study locations

1 site
  • Beijing GoBroad Hospital
    Beijing, Beijing Municipality 102206, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2025 to primary completion in Apr 2026, 12 months.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2027 → Apr 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
Apr 25, 2025
StartActual
Apr 16, 2025
Primary completionActual
Apr 25, 2026
CompletionActual
Apr 25, 2026was Apr 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The decision was not based on safety concerns. Enrolled participants will complete safety follow-up per protocol.
changed Oct 14, 2026
Sites
1 site added, 1 site removed
Show site
  • Beijing GoBroad Hospital · Beijing, China
Show 1 removed
  • Beijing GoBroad Hospital · Beijing, China
Oct 14, 2026
Study completion
Apr 25, 2027→Apr 25, 2026 (actual)
Oct 14, 2026
Enrollment
36 (estimated)→2 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Terminated
    Why stopped Sponsor decision to discontinue; the study is no longer being pursued due to sponsor strategic reprioritization and resource allocation. The decision was not based on safety concerns. Enrolled participants will complete safety follow-up per protocol.
    1 site added, 1 site removed
    Show site
    • Beijing GoBroad Hospital · Beijing, China
    Show 1 removed
    • Beijing GoBroad Hospital · Beijing, China
    Study completion Apr 25, 2027→Apr 25, 2026 (now actual)
    Enrollment 36 (estimated)→2 (actual)
    + 3 other changes: index terms, criteria formatting and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06943937
Lead sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 25, 2025
Start date
Apr 16, 2025
Primary completion
Apr 25, 2026
Completion
Apr 25, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YTS109

Start the discussion